| Identification | Back Directory | [Name]
3-(3,5-dichloro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic acid | [CAS]
2118899-51-5 | [Synonyms]
ITB-102
KP-2955
taragarestrant
3-(3,5-dichloro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic acid
2-Propenoic acid, 3-[3,5-dichloro-4-[(1R,3R)-2-(2-fluoro-2-methylpropyl)-2,3,4,9-tetrahydro-3-methyl-1H-pyrido[3,4-b]indol-1-yl]phenyl]-, (2E)- | [Molecular Formula]
C25H25Cl2FN2O2 | [MOL File]
2118899-51-5.mol | [Molecular Weight]
475.38 |
| Hazard Information | Back Directory | [Uses]
Taragarestrant (D-0502) is a potent, orally active and selective estrogen receptor degrader (SERD). Taragarestrant shows potent activity in various ER+ breast cancer cell lines and xenograft models[1][2]. | [in vivo]
Taragarestrant (D-0502) exhibits superior PK profiles suitable for clinical development[1]. | [References]
[1] Lin WY, et, al. Abstract 5776: Pharmacologic and PK/PD study of D-0502: An orally bioavailable SERD with potent antitumor activity in ER-positive breast cancer cell lines and xenograft models. 2018 Jul 1;78(13):5776.
[2] WHO Drug Information. International Nonproprietary Names for Pharmaceutical |
|
|